Monday, January 27, 2020

 


Acasti Pharma Inc
(TSX-V: ACST.VN) Add to Watchlist
$0.850
-0.020 (-2.30%)
as of Jan 27, 2020

Last 0.850
Change -0.020 (-2.30%)
Open 0.860
Prev. Close 0.870
Today's Range
0.820 0.860
52wk Range
0.670 4.050
Volume 53,924
Avg Volume 455,287

Recent Headlines
Reports 30.5% and 36.7% reduction in triglyceride levels, compared with baseline, among patients receiving CaPre at 12 and 26 weeks respectively, as well as 42.2% reduction in triglyceride levels among patients receiving CaPre while on background statin therapy at 12 weeks  (full story)
ACST: 0.64 (-0.03), ACST.VN: 0.850 (-0.020)
Trading resumes in:  (full story)
ACST: 0.64 (-0.03), ACST.VN: 0.850 (-0.020)
Expects to report Trilogy 1 topline results in January 2020  (full story)
ACST: 0.64 (-0.03), ACST.VN: 0.850 (-0.020)
The following issues have been halted by IIROC:  (full story)
ACST: 0.64 (-0.03), ACST.VN: 0.850 (-0.020)
Back in the end of 2018, a report from Moody's said that 2019 should be a standout year for the medical device industry. They added that revenue growth for device companies would be driven through innovation for most companies and categories. They were right on both counts! The numbers through 2019  (full story)
SOLY: 13.04 (-1.61), ATEC: 6.25 (-0.11), MDT: 119.23 (-0.03), IMGN: 4.56 (+0.16), ACST: 0.64 (-0.03), ACST.VN: 0.850 (-0.020)
Performance Comparison
Name Today 3-Month 1-Year
ACST.VN -2.30% -68.75% -41.78%
$TXCX -0.70% +2.86% +13.51%
$TXCI -0.65% +2.48% +13.20%
DJIA -1.57% +3.05% +15.36%
S&P 500 -1.57% +4.91% +21.72%

Key Statistics
Annual EPS -0.570
Dividend & Yield -- (--)
P/E Ratio N/A
Market Capitalization, $K 76,520
Weighted Alpha -18.60
Standard Deviation -0.10
Profit Margin --
Beta -0.325

Growth Rates
YTD -73.44%
1-Year -40.41%
3-Year -49.42%
© 2020 Market data provided and hosted by Barchart Market Data Solutions. Fundamental company data provided by Morningstar and Zacks Investment Research. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.